Your browser doesn't support javascript.
loading
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Antoniotti, Carlotta; Boccaccino, Alessandra; Seitz, Robert; Giordano, Mirella; Catteau, Aurélie; Rossini, Daniele; Pietrantonio, Filippo; Salvatore, Lisa; McGregor, Kimberly; Bergamo, Francesca; Conca, Veronica; Leonetti, Simone; Morano, Federica; Papiani, Giorgio; Tamburini, Emiliano; Bensi, Maria; Murgioni, Sabina; Ross, Douglas Teller; Passardi, Alessandro; Boquet, Isabelle; Nielsen, Tyler J; Galon, Jérôme; Varga, Matthew Gordon; Schweitzer, Brock L; Cremolini, Chiara.
  • Antoniotti C; Department of Translational Research and New Technologies in Medicine and Surgery - Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Boccaccino A; Department of Translational Research and New Technologies in Medicine and Surgery - Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Seitz R; Oncocyte Inc, Nashville, Tennessee.
  • Giordano M; Department of Translational Research and New Technologies in Medicine and Surgery - Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Catteau A; Veracyte, Marseille, France.
  • Rossini D; Department of Translational Research and New Technologies in Medicine and Surgery - Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Salvatore L; Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.
  • McGregor K; Oncologia Medica, Università Cattolica del Sacro Cuore, Roma, Italy.
  • Bergamo F; Oncocyte Inc, Nashville, Tennessee.
  • Conca V; Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Leonetti S; Department of Translational Research and New Technologies in Medicine and Surgery - Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Morano F; Department of Life Science, School of Advanced Studies Sant'Anna, Pisa, Italy.
  • Papiani G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Tamburini E; Unità Complessa Oncologia di Ravenna, AUSL Romagna, Ravenna, Italy.
  • Bensi M; Oncology and Palliative Care Department, Tricase City Hospital, Tricase, Italy.
  • Murgioni S; Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.
  • Ross DT; Oncologia Medica, Università Cattolica del Sacro Cuore, Roma, Italy.
  • Passardi A; Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Boquet I; Oncocyte Inc, Nashville, Tennessee.
  • Nielsen TJ; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Galon J; Veracyte, Marseille, France.
  • Varga MG; Oncocyte Inc, Nashville, Tennessee.
  • Schweitzer BL; INSERM, Laboratory of Integrative Cancer Immunology, Paris, France.
  • Cremolini C; Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Paris, France.
Clin Cancer Res ; 29(12): 2291-2298, 2023 06 13.
Article en En | MEDLINE | ID: mdl-37022350

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Recto / Neoplasias Colorrectales / Neoplasias del Colon Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Recto / Neoplasias Colorrectales / Neoplasias del Colon Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article